EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Efficacy of Metastasis-Directed Radiation Therapy to Prolong Systemic Therapy for Patients with Oligoprogressive Metastatic Breast Cancer

Alexis LeVee iD, Hannah Young, Stephanie Yoon iD, Scott Glaser, Shengyang Wu, Joanne Mortimer iD, Jose G Bazan

Cancers · 26.06.2025 · 17 (13) · 2153

DOI: 10.3390/cancers17132153 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancers, online erschienen am 26.06.2025. Verfasst von Alexis LeVee und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, City of Hope National Medical Center, Duarte, CA 91010, USA. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Clinical trials have shown mixed results regarding the benefit of metastasis-directed radiation therapy (MDRT) in oligoprogressive (OP) metastatic breast cancer (MBC), leading to ongoing debate about its role. This study aimed to investigate whether MDRT can prolong the duration of systemic therapy for ≥6 months in patients with OP MBC.

Methods

This retrospective cohort study included patients with MBC who received MDRT for OP disease between December 2017 and March 2023. Patients who received MDRT to the brain were excluded. Medical records were reviewed through July 2024. The primary endpoint was the proportion of patients remaining on the same systemic therapy for ≥6 months post-MDRT.

Results

In total, 52 patients with OP MBC treated with MDRT were included, with 36 (69%) with HR+/HER2- disease, 10 (19%) with HER2+ disease, and 6 (12%) with TNBC. Among the 47 patients with follow-up data available, 28 (60%) remained on their systemic therapy at 6 months, including 65% (22/34) of patients with HR+/HER2- disease, 56% (5/9) with HER2+ disease, and 25% (1/4) with TNBC (p = 0.30). Among the 38 patients with a follow-up time of at least 1 year post-MDRT, 47% (18/38) remained on the same systemic therapy. The median time to next systemic therapy and median PFS were 6.9 months (95% CI, 5.7–14.7) and 6.2 months (95% CI, 4.1–9.7), respectively.

Conclusions

Over half of patients with OP MBC remained on the same systemic therapy for at least 6 months following MDRT, which suggests that MDRT may help prolong systemic therapy duration for select patients.

Schlagwörter

Stichwörter der Autor:innen

breast cancermetastasis-directed therapyoligometastasesoligoprogressiveradiation therapy

Autor:innen und Institutionen

  • Department of Medical Oncology, City of Hope National Medical Center, Duarte, CA 91010, USA.
  • Department of Radiation Oncology, City of Hope National Medical Center, Duarte, CA 91010, USA.

ORCID-Profile: Alexis LeVee, Stephanie Yoon, Joanne Mortimer

Zitieren

APA

LeVee, A., Young, H., Yoon, S., Glaser, S., Wu, S., Mortimer, J., & Bazan, J. G. (2025). Efficacy of Metastasis-Directed Radiation Therapy to Prolong Systemic Therapy for Patients with Oligoprogressive Metastatic Breast Cancer. Cancers, 17(13), 2153. https://doi.org/10.3390/cancers17132153

Vancouver

LeVee A, Young H, Yoon S, Glaser S, Wu S, Mortimer J, et al. Efficacy of Metastasis-Directed Radiation Therapy to Prolong Systemic Therapy for Patients with Oligoprogressive Metastatic Breast Cancer. Cancers. 2025;17(13):2153. doi:10.3390/cancers17132153

BibTeX
@article{LeVee2025,
  author = {LeVee, Alexis and Young, Hannah and Yoon, Stephanie and Glaser, Scott and Wu, Shengyang and Mortimer, Joanne and Bazan, Jose G},
  title = {Efficacy of Metastasis-Directed Radiation Therapy to Prolong Systemic Therapy for Patients with Oligoprogressive Metastatic Breast Cancer},
  journal = {Cancers},
  year = {2025},
  volume = {17},
  number = {13},
  pages = {2153},
  doi = {10.3390/cancers17132153}
}
Kostenlos starten →